Going Global Weekly: Innovative Drug Data and Regulatory Qualifications Go Global in Clusters as Tech IPOs See Pricing and Terminations Side by Side-20261030

Overseas M&A

1. CONCORD NE (00182.HK): Its wholly-owned subsidiary Red River entered into a disposal agreement with Uva Creek Solar Holdings, LLC and ESI Energy to sell 100% of the equity interests in two target project companies, Gail Mountain and Grape Creek, for a maximum total consideration of approximately USD 29.98 million (approximately RMB 200.57 million), with the buyer wholly owned by NextEra Energy Resources, LLC; the targets are proposed photovoltaic projects in Borden County, Texas, with nameplate generation capacities of 244 MW and 301 MW respectively, totalling 545 MW, and the consideration is payable in four instalments against four milestones, namely completion, execution of offtake agreements, issuance of a notice to proceed and commercial operation; the unaudited net asset value of the target project companies was approximately USD 2.01 million as of October 21, and the maximum unaudited gain is expected to be approximately USD 27.97 million; the disposal constitutes a discloseable transaction, and the long-stop date for completion is December 1, 2026.

Overseas Orders and Bid Wins

1. CHALIECO (02068.HK): Announced on October 26 that it had won the bid for the 2.4 million tonnes per annum alumina project of Binh Phuoc Ore Mining and Beneficiation Joint Stock Company in Vietnam and had received the letter of acceptance, on an engineering, procurement and construction (EPC) turnkey basis, with a total contract price of USD 833 million (equivalent to approximately RMB 5.595 billion) and a construction period of 27 months from the effective date of the contract; the scope of work covers design, material and equipment supply, construction, installation, commissioning and training for the alumina plant; the contract has not yet been formally signed, and the company cautioned that the project is located overseas and may face overseas operating risks such as changes in the local political environment and foreign exchange controls.

Overseas Projects and Operations

1. BRETON (01333.HK): Announced on October 28 that it entered into a strategic cooperation letter of intent with Golden Construction Co., Ltd., under which the two parties intend to establish a long-term cooperation in the field of industrial synergy between green energy and smart mining in the Democratic Republic of the Congo, and intend to advance energy supporting projects for smelters in phases over the next three years as circumstances permit, with an intended total construction scale of 275 MW of photovoltaic capacity and 400 MWh of energy storage, and to promote the deployment and procurement of electric mining trucks and a demonstration fleet of autonomous driving electric mining trucks, building an integrated demonstration of green power, electrification and autonomous driving; the letter of intent is valid for five years and is a framework arrangement, with no legally binding formal agreement yet entered into.

2. HUTCHMED (00013.HK): Announced on October 26 that results from the global Phase III SAFFRON study were presented at the Presidential Symposium of the 2026 ESMO Congress (LBA6) and simultaneously published in the New England Journal of Medicine: among 338 patients with advanced non-small cell lung cancer harbouring EGFR mutations with MET overexpression or amplification who had progressed after osimertinib treatment, the savolitinib plus osimertinib group recorded a median progression-free survival of 7.6 months versus 5.4 months in the control group, reducing the risk of disease progression or death by 45%; median overall survival was 17.8 months versus 12.9 months, reducing the risk of death by 32%. Based on this study, a new drug application for the combination therapy has been submitted to the U.S. FDA, and applications in Europe and Japan are progressing as planned.

3. SKB BIO (06990.HK): Announced on October 25 that Phase III results for the TROP2 ADC sacituzumab tirumotecan in two lung cancer studies were presented at the ESMO Congress, one of which was simultaneously published in the New England Journal of Medicine: in the OptiTROP-Lung06 study of the product combined with pembrolizumab as first-line treatment for PD-L1-negative advanced non-squamous non-small cell lung cancer, median progression-free survival was 15.0 months versus 5.7 months in the control group, reducing the risk of disease progression or death by 51%.

4. ALPHAMAB-B (09966.HK): Announced on October 26 that two Phase III results for anbenitamab, developed jointly with JMT-Bio, a subsidiary of CSPC PHARMA, were presented as late-breaking oral presentations at ESMO: the KN026-003/Healer study enrolled 885 patients with HER2-positive advanced breast cancer, and first-line treatment reduced the risk of disease progression or death by 54% (HR 0.46), with the results published simultaneously in the New England Journal of Medicine and the marketing application accepted and granted priority review; in the KC-WISE study of 246 patients with HER2-positive gastric cancer who had failed prior trastuzumab treatment, median overall survival was 19.6 months versus 9.6 months in the control group.

5. LEADS BIOLABS-B (09887.HK): Announced on October 26 that updated data from four studies of LBL-024 were presented at the ESMO Congress: the Phase IIb study (96 patients) of monotherapy in third-line or later extrapulmonary neuroendocrine carcinoma was presented as a late-breaking oral presentation, with a median overall survival of 8.7 months against a historical median overall survival of 3 to 4 months, and a 12-month overall survival rate of 39.4%.

Regulatory and Compliance

1. LIFETECH SCI (01302.HK): Disclosed on October 30 that on October 29 the IBS bioresorbable drug-eluting coronary stent system, independently developed by its subsidiary Biotyx Medical, obtained EU CE MDR certification, making it the world's first iron-based coronary stent system to obtain marketing approval.

2. ZHAOKE OPHTH-B (06622.HK): Announced on October 27 that its Guangzhou Nansha production base obtained Good Manufacturing Practice (GMP) certification from the Australian Therapeutic Goods Administration (TGA); Australia is a full member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), whose inspection results are highly mutually recognised among member authorities, and the company said that, as it continues to advance overseas registration and commercialisation of multiple products, the certification will support the entry of its products into more overseas markets.

3. HUTCHMED (00013.HK): Announced on October 29 that sovleplenib, an oral spleen tyrosine kinase (Syk) inhibitor, has been granted orphan drug designation by the U.S. FDA for the treatment of primary immune thrombocytopenia, and would be eligible for seven years of U.S. market exclusivity if approved for the designated indication; two new drug applications for this indication in China are under review by the National Medical Products Administration.

Overseas Financing

1. XINDE SEMI (07672.HK): Published its global offering announcement on October 30 for a global offering of 106,562,500 H shares at a maximum offer price of HKD 9.60 per share, raising approximately HKD 1.023 billion on that basis, with the H shares expected to be listed on the Main Board of the Stock Exchange on or around November 10; the company will not appoint a stabilising manager.

2. HOSIN ELEC (02681.HK): Published its global offering announcement on October 30 for a global offering of 14,717,200 H shares at an offer price of HKD 82.90 per share, raising approximately HKD 1.220 billion on that basis, with the H shares expected to commence trading on November 12 and China Securities (International) Finance Limited acting as stabilising manager.

3. DENGLIN (09917.HK): Published its global offering announcement on October 30 for a global offering of 6,125,000 H shares at an offer price of HKD 288 per share, raising approximately HKD 1.764 billion on that basis, with the Hong Kong public offering running from October 30 to November 5 and listing expected on November 10; the company passed the listing hearing of the Stock Exchange on October 26 and ranked third in China's enterprise AI GPGPU market by 2025 revenue.

4. NEAUTUS (02206.HK): Passed the listing hearing of the Stock Exchange on October 26 and published its global offering announcement on October 30 for a global offering of 6,517,300 H shares at an offer price of HKD 50.55 per share, raising approximately HKD 329 million on that basis.

5. ADASPACE: Disclosed on October 29 that it had passed the listing hearing of the Stock Exchange, with Guotai Junan International acting as sole sponsor; the company is an AI satellite enterprise that successfully developed and launched the world's first constellation of 12 AI intelligent computing satellites in May 2025, with revenue rising from RMB 507.5 million in 2023 to RMB 702.7 million in 2025.

6. SINOTAU: Disclosed on October 28 that it had passed the listing hearing of the Stock Exchange, with GF Securities, CICC and CITIC Securities acting as joint sponsors; the company is a radiopharmaceutical enterprise with a pipeline of 13 assets, and its core product XTR008, a 177Lu-labelled radioligand targeting somatostatin receptors for neuroendocrine tumours, is expected to be approved in December 2026.

7. SUNWODA (300207.SZ): Announced on October 29 that its board approved the termination of the issue of H shares and listing on the Main Board of the Stock Exchange, based on comprehensive consideration of the market environment, changes within the company and its development plans; the termination falls within the scope of the authority delegated by the shareholders' meeting to the board to handle at its full discretion and does not require submission to the shareholders' meeting for review.

8. YUSYS TECHNOLOGIES (300674.SZ): Announced on October 29 that its board approved a resolution to terminate the issue of H shares and listing on the Stock Exchange, made prudently based on comprehensive consideration of the market environment and its own development plans; the termination is subject to separate submission to the shareholders' meeting for review.

9. MICRO-INTELLIGENCE (03275.HK): Announced on October 25 that, after considering a number of factors including prevailing market conditions, it has decided to delay its global offering and the proposed listing on the Main Board of the Stock Exchange; the international underwriting agreement will not be entered into, and application monies for the Hong Kong public offering will be refunded in full without interest; the company said it remains committed to completing the global offering and listing in due course.

10. MEITUAN-W (03690.HK): Announced on October 28 that on October 27 it entered into purchase agreements with the initial purchasers for the issue of RMB 4.5 billion of 2.50% notes due 2031 and RMB 3.5 billion of 3.10% notes due 2036, totalling RMB 8 billion; the net proceeds will be used principally to refinance existing offshore debt and for general corporate purposes.

11. SANDS CHINA LTD (01928.HK): Announced on October 28 the issue of USD 700 million of 6.400% notes due 2032 and USD 300 million of 6.700% notes due 2033, totalling USD 1 billion, with estimated net proceeds of approximately USD 989 million, to be used together with cash on hand to redeem in full the USD 700 million of 2.300% notes due March 2027, to repay the outstanding balance under the 2024 SCL revolving facility and for general corporate purposes.

12. SFQ GLOBAL (01953.HK): Announced on October 29 the completion of a placing of 215 million new shares at a placing price of HKD 0.973 per share to not fewer than six placees, raising net proceeds of approximately HKD 208.3 million, of which approximately 93.6% will be used for the working capital of new energy power station construction contracting projects and approximately 2.4% for business expansion in Southeast Asia and Africa.

Overseas Operating Data

1. COSCO SHIP PORT (01199.HK): Announced on October 29 its results for the first three quarters of 2026, with total revenue of USD 1.39 billion, up 12.55% year on year, and profit attributable to shareholders of USD 316 million, up 19.66% year on year; gross profit margin was 26.45%, and operating margin improved from 16.11% to 20.86%.

NewTimeSpace Going Global Observation

This week's overseas expansion story ran along three main threads. First, clinical evidence and compliance qualifications for innovative drugs went global in clusters: Phase III and Phase II data from a number of pharmaceutical companies were disclosed at the ESMO Congress and simultaneously published in the New England Journal of Medicine, while LIFETECH SCI, ZHAOKE OPHTH-B and HUTCHMED respectively obtained EU CE MDR certification, Australian TGA GMP certification and U.S. FDA orphan drug designation, extending the credentials of Chinese drugs and devices going global from pipeline licensing to production systems and regulatory review. Second, the pipeline of companies listing in Hong Kong diverged: XINDE SEMI, HOSIN ELEC, DENGLIN and NEAUTUS priced and launched their offerings in quick succession, while ADASPACE and SINOTAU passed the listing hearing one after the other; yet SUNWODA and YUSYS TECHNOLOGIES successively terminated their H-share issues, BLUEFOCUS had also earlier terminated its H-share listing plan, and MICRO-INTELLIGENCE announced a delay after its offering, as technology and manufacturing companies take a more pragmatic view of the issuance window. Third, overseas orders and asset transactions advanced in parallel: CHALIECO locked in a large alumina EPC contract in Vietnam, and CONCORD NE sold a U.S. photovoltaic project under construction to a buyer under NextEra, with the going-global path flowing in both directions between taking on and transferring assets.

This article is for information purposes only and does not constitute any investment advice.